What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
His primary areas of study are Internal medicine, Cancer, Clinical trial, Retrospective cohort study and Surgery.
His Internal medicine study frequently draws connections between related disciplines such as Oncology.
His Cancer study integrates concerns from other disciplines, such as Odds ratio and Lung cancer.
His work carried out in the field of Clinical trial brings together such families of science as Psychological intervention, Gerontology, Cross-sectional study, Randomized controlled trial and Alternative medicine.
His Gerontology research incorporates themes from Surgical oncology, Ethnic group and Public health.
His research integrates issues of COPD, Epidemiology and Cohort study in his study of Surgery.
His most cited work include:
- Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review (1400 citations)
- Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities (1331 citations)
- Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study (997 citations)
What are the main themes of his work throughout his whole career to date?
Cary P. Gross focuses on Internal medicine, Cancer, Breast cancer, Oncology and Family medicine.
Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Surgery.
His Cancer study incorporates themes from Odds ratio, Logistic regression, Epidemiology and Clinical trial.
The study incorporates disciplines such as Stage, Adjuvant, Gynecology and Radiation therapy in addition to Breast cancer.
As part of his studies on Oncology, Cary P. Gross frequently links adjacent subjects like Hazard ratio.
He has researched Family medicine in several fields, including Health care and MEDLINE.
He most often published in these fields:
- Internal medicine (41.33%)
- Cancer (27.86%)
- Breast cancer (21.83%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (41.33%)
- Cancer (27.86%)
- Oncology (21.67%)
In recent papers he was focusing on the following fields of study:
Cary P. Gross mainly focuses on Internal medicine, Cancer, Oncology, Family medicine and MEDLINE.
His work in Breast cancer, Odds ratio, Chemotherapy, Prostate cancer and Cohort are all subfields of Internal medicine research.
His Breast cancer research is multidisciplinary, incorporating elements of Radiation therapy and Epidemiology.
His studies deal with areas such as Quality and Lung cancer as well as Cancer.
In his study, Patterns of care is strongly linked to Immune checkpoint inhibitors, which falls under the umbrella field of Oncology.
His MEDLINE research integrates issues from Medical physics and Emergency medicine.
Between 2018 and 2021, his most popular works were:
- Racial and Ethnic Disparities in Population-Level Covid-19 Mortality. (76 citations)
- Assessment of the Prevalence of Medical Student Mistreatment by Sex, Race/Ethnicity, and Sexual Orientation (32 citations)
- Effects of rising drug costs on efforts to control overall cost at a large academic cancer center. (19 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
The scientist’s investigation covers issues in Internal medicine, Breast cancer, Odds ratio, Logistic regression and Cancer.
His Internal medicine research incorporates elements of Guideline and Oncology.
His Breast cancer research is multidisciplinary, incorporating perspectives in Cost–benefit analysis, Epidemiology and Radiology.
His study in Odds ratio is interdisciplinary in nature, drawing from both Emergency department, Operative time and Anxiety.
Cary P. Gross interconnects Radiation therapy, Prostate cancer and Specialty in the investigation of issues within Logistic regression.
His research ties Emergency medicine and Cancer together.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
